Medication guide
Mounjaro
tirzepatide
Mounjaro is a once-weekly tirzepatide injection labeled to improve glucose control in adults and children age 10 and older with type 2 diabetes. Its pediatric maximum dose differs from the adult maximum, and it is not the tirzepatide brand labeled for chronic weight management.
FDA label revision: January 2026 · Page updated 2026-09-14
What is Mounjaro?
Mounjaro is a once-weekly tirzepatide injection labeled to improve glucose control in adults and children age 10 and older with type 2 diabetes. Its pediatric maximum dose differs from the adult maximum, and it is not the tirzepatide brand labeled for chronic weight management.[1]
How it works
Tirzepatide activates both GIP and GLP-1 receptors. Its effects on incretin signaling influence glucose regulation, appetite, and gastric emptying. The approved purpose, formulation, dose, and monitoring plan depend on this exact brand rather than the ingredient name alone.[1]
Indications
- Adults and pediatric patients age 10 years and older: Glycemic control for type 2 diabetes alongside diet and exercise.[1]
Formulations and dosing
Injection
Subcutaneous · Once weekly
Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg per dose
Adult dosing
Starting: 2.5 mg once weekly for 4 weeks
- Increase to 5 mg once weekly after 4 weeks
- If needed, increase in 2.5 mg increments only after at least 4 weeks on the current dose
Maintenance: 5 mg to 15 mg once weekly
Maximum: 15 mg once weekly
[1]Pediatric dosing
Starting: 2.5 mg once weekly for 4 weeks
- Increase to 5 mg once weekly after 4 weeks
- If needed, increase to 7.5 mg and then 10 mg only after at least 4 weeks on the current dose
Maintenance: 5 mg to 10 mg once weekly
Maximum: 10 mg once weekly
[1]What Mounjaro is not approved for
Mounjaro is not labeled for chronic weight management. Zepbound contains the same active ingredient but has weight-management and obstructive-sleep-apnea indications.[1,2]
Warnings
- The label carries a boxed warning about thyroid C-cell tumors in rats. Mounjaro is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.[1]
- Acute pancreatitis has been observed. Persistent severe abdominal pain, which may radiate to the back, requires prompt evaluation.[1]
- Using Mounjaro with insulin or an insulin secretagogue can increase hypoglycemia risk; those medicines may require clinician-directed adjustment.[1]
- Delayed gastric emptying can reduce the effectiveness of oral hormonal contraceptives after initiation and each dose increase; the label provides temporary backup-contraception instructions.[1]
- People with a history of diabetic retinopathy should be monitored because rapid improvement in glucose can temporarily worsen retinopathy.[1]
Contraindications
If a dose is missed
The label says to take a missed dose within 4 days (96 hours). After that, skip it and resume the normal weekly schedule; keep at least 3 days between doses.[1]
Common adverse reactions
Common adult reactions include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain.[1]
Important label distinctions
The label includes patients age 10 years and older with type 2 diabetes. The pediatric maximum is 10 mg weekly, while the adult maximum is 15 mg weekly.[1]
Product-specific evidence
Mounjaro evidence should be interpreted for its type 2 diabetes populations and dose ranges. Weight-loss results from Zepbound obesity trials do not automatically describe Mounjaro use.[1]
Cost and coverage
Insurance coverage may depend on the diagnosis, plan formulary, prior-authorization rules, and the exact brand. Before committing to care, confirm the medication cost, clinical or subscription fees, laboratory costs, refill process, and what happens if coverage changes. Prices and coverage should be checked directly rather than assumed from an advertised starting price.
Lifestyle considerations
Medication does not automatically preserve muscle, improve fitness, or meet nutrition needs. A practical plan can include manageable meals, adequate fluid, progressive strength work, aerobic activity, sleep, and follow-up adapted to symptoms and health history. Reduced appetite is not a reason to ignore persistent difficulty eating or drinking.
Questions to ask your clinician
- What glucose goal and monitoring plan are we using?
- Do my insulin or sulfonylurea doses need review?
- Which adult or pediatric titration schedule applies?
- Do oral medicines, including contraception, need special planning?
- Which eye, kidney, or gastrointestinal symptoms should prompt a call?